Judge Hacks Away At Allergan's Restasis Patents
A federal judge ruled Monday that claims in several patents covering Allergan PLC's dry-eye drug Restasis are invalid, dealing a blow to the drugmaker just weeks after it transferred the patents...To view the full article, register now.
Already a subscriber? Click here to view full article